Sign In
Buy RNA
$12.17
-0.0800 (-0.653%)
At Close: Jun 03, 2026
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
11:23am, Sunday, 19'th May 2024
Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform. Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1. The c
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
09:00am, Wednesday, 15'th May 2024
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
04:05pm, Thursday, 09'th May 2024
Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE4
Avidity Biosciences to Participate in Upcoming Investor Conference
04:05pm, Wednesday, 08'th May 2024
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 22'nd Apr 2024
SAN DIEGO , April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences to Participate in Upcoming Investor Conferences
09:00am, Wednesday, 27'th Mar 2024
SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st Mar 2024
SAN DIEGO , March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Dyne: H2 2024 Muscle Disease Data Could Boost Value
02:48pm, Tuesday, 05'th Mar 2024
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
11:35am, Monday, 04'th Mar 2024
Top-notch biotech stock Avidity collapsed Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
01:39pm, Thursday, 29'th Feb 2024
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences Honors Rare Disease Day®
12:00pm, Thursday, 29'th Feb 2024
SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
07:00am, Thursday, 29'th Feb 2024
Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellingto
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
06:20pm, Wednesday, 28'th Feb 2024
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.88 per share a year ago.
Avidity Biosciences to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 27'th Feb 2024
SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
3 Highly Rated Biotech Stocks to Buy for 300% Gains
06:55am, Monday, 26'th Feb 2024
Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener
